Dihydropyrimidine dehydrogenase (EC 1.3.1.2; DPD) is the rate-limiting enzyme in pyrimidine catabolism converting the pyrimidine bases thymine and uracil to their dihydro derivatives (Webster et al 1995) . DPD deficiency (McKusick 274270) has so far been reported in about 30 patients, most of them children (Webster et al 1995) . The clinical phenotype is variable. Affected individuals have in many cases been detected when they have been investigated because of unspecific neurological symptoms. In some patients, symptoms have been induced by 5-fluorouracil, an anticancer drug which is also metabolized through DPD. We describe the first two Finnish cases of DPD deficiency: a girl whose first symptom was status epilepticus at the age of 7 years, and her so far symptom-free 5-year-old sister.
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A 7-year-old girl was admitted to Turku University Hospital because of unconsciousness. She is the elder of two children of nonconsanguineous healthy Finnish parents. She was born at term after a normal pregnancy, and her growth and psychomotor development were normal. On admission, she was reacting to pain but needed assisted ventilation. Her EEG showed a generalized slowing of background activity but no irritative features or local abnormalities. Routine clinical laboratory parameters, spinal fluid analysis, and brain CT were normal. No infectious agents were found. She recovered in 24 hours without any symptoms, and the episode was tentatively classified as status epilepticus. After 3 weeks, she was admitted to the hospital for further examinations. In the ward she had her first partial, secondarily generalized epileptic attack. EEG recording indicated an irritative activity in the right occipital region. Her brain MRI was normal. Antiepileptic medication with oxcarbazepine was started, and she has been without seizures since then.
Urinary organic acids were analyzed by gas chromatography-mass spectrometry after solid-phase extraction and thymine and uracil concentrations by cation exchange chromatography using UV detection (van Gennip et al 1995) . A urine sample from the patient indicated increased concentrations of thymine and uracil (163 and 191 µmol/mmol creatinine, respectively), and serum concentrations of thymine (22 µmol/L) and uracil (23 µmol/L) were also elevated. The symptom-free sibling also had increased levels of thymine (227 µmol/mmol creatinine) and uracil (275 µmol/mmol creatinine) in her urine, and the plasma concentrations of thymine (25 µmol/L) and uracil (18µmol/L) were increased. Her mother and father had nondetectable serum concentrations of thymine, and very low levels of uracil (0.40 and 0.15 µmol/L, respectively). Their urine samples contained trace amounts of thymine and uracil (the father had uracil) ~ (6 µmol/mmol creatinine). DPD activities (nmol/mg protein per h) in cultured skin fibroblasts were as follows: the patient and her sister nondetectable; mother 0.66; father 0.51; controls (n =16) 1.00 ± 0.76 (mean ± SD). The molecular analysis of DPD gene was carried out as described recently (Vreken et al 1996) , and indicated that both sisters were homozygous for G → A mutation in an invariant splice-donor site. As expected, both parents were heterozygous for this mutation.
Although the clinical manifestations of DPD deficiency are unspecific and variable, the majority of patients have convulsive disorders or a family history of epilepsy (Webster et al 1995) . Epilepsy usually appears during the first decade. The mode of inheritance of DPD deficiency is autosomal recessive. The gene frequency is not known, but based on the Dutch experience it may be rather high (van Gennip et al 1995) . The mutation leads to skipping of the 165 nt exon immediately upstream of the splice-donor site in the process of DPD pre-mRNA splicing. As a result, the mature DPD mRNA lacks a 165 nt segment encoding amino acid residues 581-635. The resulting mutant DPD protein has no detectable residual activity (Vreken et al 1996) . The same mutation has also been found in two homozygous, unrelated Dutch patients and in a patient from Denmark (Vreken et al 1996) , suggesting homogeneity in DPD-deficient patients in northern Europe.
